Psoriatic arthritis (PsA), a serious and potentially disabling condition, affects approximately 30% of patients with psoriasis, with the joint involvement often occurring about 10 years after the appearance of skin disease. PsA causes not only physical and functional impairments but also has a negative impact on overall quality of life. While dermatologists have an important role in early detection of PsA, patients often have overlapping treatment needs that require collaborative care between dermatologists and rheumatologists.
Recent U.S. Food and Drug Administration (FDA) approvals of several agents for moderate-to-severe PsA have expanded the treatment armamentarium, and the management paradigm continues to evolve. However, PsA continues to be under-recognized, misdiagnosed, and inadequately treated.
In this CMEOCast podcast, expert faculty focus on the latest evidence on screening patients for PsA, individualizing treatment that considers patient-reported outcomes (PROs), and using patient-centered approaches for care, with the goal of optimizing patient outcomes.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by educational grants from Celgene Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Dermatologists, rheumatologists, nurse practitioners (NPs), physician associates (PAs), and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Ogdie-Beatty reports that she receives grants from Amgen Inc.; Novartis; and Pfizer Inc. She is a consultant for AbbVie Inc.; Amgen Inc.; Bristol Myers Squibb Company; Celgene Corporation; Corrona; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Novartis; and Pfizer Inc. Her husband has received other financial or material support in the form of royalties from Novartis.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.